The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
L. Thomas, Eric Martel, Wolfgang Rist, Ingo Uphues, Dieter W Hamprecht, Heike Neubauer, Robert Augustin•April 1, 2024•10 citations
Chat with this paper
Extract insights, manage references, and accelerate your research
Continue your research
– It's free
Abstract
To describe the biomarker strategy that was applied to select survodutide (BI 456906), BI 456908 and BI 456897 from 19 dual glucagon receptor (GCGR)/ glucagon‐like peptide‐1 receptor (GLP‐1R) agonists for in‐depth pharmacological profiling, which led to the qualification of survodutide as the clinical development candidate.